Dec 8, 2019

Immunotherapy in pediatric acute lymphoblastic leukemia

Cancer Metastasis Reviews
Hiroto Inaba, Ching-Hon Pui


The 5-year survival rate for children and adolescents with acute lymphoblastic leukemia (ALL) has improved to more than 90% in high-income countries. However, further increases in the intensity of conventional chemotherapy would be associated with significant adverse effects; therefore, novel approaches are necessary. The last decade has seen significant advances in targeted therapy with immunotherapy and molecular therapeutics, as well as advances in risk stratification for therapy based on somatic and germline genetic analysis and monitoring of minimal residual disease. For immunotherapy, the approval of antibody-based therapy (with blinatumomab in 2014 and inotuzumab ozogamicin in 2017) and T cell-based therapy (with tisagenlecleucel in 2017) by the US Food and Drug Administration has significantly improved the response rate and outcomes in patients with relapsed/refractory B-ALL. These strategies have also been tested in the frontline setting, and immunotherapy against a new ALL-associated antigen has been developed. Incorporating effective immunotherapy into ALL therapy would enable the intensity of conventional chemotherapy to be decreased and thereby reduce associated toxicity, leading to further improvement in survival ...Continue Reading

  • References
  • Citations1


  • We're still populating references for this paper, please check back later.
  • References
  • Citations1

Mentioned in this Paper

Acute Leukemia
BCR protein, human
Antibody Therapy
Adverse Effects
Administration of Antineoplastic Agent
Toxic Effect
Monitoring - Action
Neoplasm, Residual

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Related Papers

Clinical Advances in Hematology & Oncology : H&O
Shilpa PaulElias J Jabbour
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Adam C RobinsonAnthony J Perissinotti
© 2020 Meta ULC. All rights reserved